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Background: Recently designed sulfated low molecular weight lignins (LMWLs) function as powerful inhibitors of coagulation through allosteric 
disruption of thrombin’s catalytic activity. Sulfated LMWLs are a unique class of anticoagulants due to their unique molecular scaffold. Prior studies 
have shown these novel anticoagulants exhibit nanomolar potency and function as noncompetitive inhibitors of thrombin by binding to thrombin’s 
heparin binding site. Although extensive indirect evidence exists that sulfated LMWLs are capable of altering the active site of thrombin, direct 
evidence that sulfated LMWLs binding to the heparin binding site of thrombin were actually altering the conformation of the active site or the 
geometry of the catalytic triad has yet to be demonstrated.
Methods: To address this, we designed three experiments capable of demonstrating structural changes within thrombin’s active site. These 
experiments involved para-amionbenzamidine (PABA), a non-covalent, fluorescent active site binding probe, as well as the covalent fluorescent 
probes, dansyl labeled thrombin (TH-D) and fluorescein labeled thrombin (TH-F) which are bound to the crucial active site amino acids Ser195 and 
His57, respectively.
Results: We demonstrate that sulfated LMWLs displace ~100% of PABA from the thrombin active site compared to ~30% of PABA by heparin. The 
interaction of our sulfated LMWLs with TH-D resulted in a decrease in dansyl fluorescence ranging 17-61% while no interaction was detected with 
heparin. The interaction between sulfated LMWLs and TH-F showed a decrease in fluorescence ranging from 60% - 87% while only a 33% decrease in 
fluorescence in the presence of heparin was observed.
Conclusions: Combined, these studies show that heparin, does not alter Ser195 and is only capable of making small changes to the overall 
structure of the thrombin active site and His57. In contrast, sulfated LMWLs, which are a novel class of allosteric thrombin inhibitors are capable of 
making significant changes to the overall structure of the thrombin binding site as well as inducing significant changes in the molecular orientation 
of the Ser195 and His57 within the thrombin active site.
